Roivant Sciences Director Melissa Epperly Receives Annual Equity Grants
Roivant Sciences Ltd.
Subscribe to track ROIV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 4 Filed for Roivant Sciences Ltd. ($ROIV) ā¢ Insider: Melissa B. Epperly (Director) ā¢ Transaction Date: September 16, 2026 ā¢ Type: Grant / Award (Code A) ā¢ Securities Transacted: 5,054 Common Shares (RSUs) at $0.00 & 10,531 Stock Options (strike $39.57) ā¢ Shares Owned After: 14,954 Common Shares ā¢ Significance: Low (Routine Annual Director Compensation)
Comprehensive Analysis
Executive Summary
On September 18, 2026, Roivant Sciences Ltd. ($ROIV) director Melissa B. Epperly reported the acquisition of equity awards dated September 16, 2026. The transaction consists of an annual award of restricted stock units (RSUs) and stock options granted under the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.
Transaction Breakdown
-
Restricted Stock Units (RSUs):
- Shares Acquired: 5,054 Common Shares
- Price per Share: $0.00
- Total Consideration: $0.00
- Vesting Terms: Vests 100% on September 16, 2027, subject to continued service.
- Resulting Beneficial Ownership: 14,954 common shares held directly.
-
Stock Options:
- Options Granted: 10,531 options to purchase Common Shares
- Exercise Price: $39.57 per share
- Expiration Date: September 15, 2036
- Vesting Terms: Vests and becomes exercisable 100% on September 16, 2027.
Market & Trading Significance
This filing reflects routine annual equity compensation awarded to a non-employee director in accordance with standard governance and compensation schedules. Because the transactions are compensation-based grants rather than discretionary open-market purchases or sales, the trading significance is rated Low.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.